A hidden cause of the reproducibility crisis is how researchers select models like cell lines or mice. The choice is often driven by convenience—what a neighboring lab has available—rather than a systematic evaluation of which model is best suited to answer the specific scientific question.

Simple cell viability screens fail to identify powerful drug combinations where each component is ineffective on its own. AI can predict these synergies, but only if trained on mechanistic data that reveals how cells rewire their internal pathways in response to a drug.

Incorporate well-characterized compounds with known, consistent effects into every separate experimental group. These "anchors" act as internal calibration points, enabling reliable comparison of results across different experimental sets that would otherwise be difficult to correlate directly.

To mitigate data variations caused by running experiments on different days (batch effects), Noetik employs a sophisticated arraying strategy. They take dozens of samples from a single tumor and distribute them across multiple, randomized arrays, ensuring each patient is represented in different batches for robust calibration and model training.

The most valuable lessons in clinical trial design come from understanding what went wrong. By analyzing the protocols of failed studies, researchers can identify hidden biases, flawed methodologies, and uncontrolled variables, learning precisely what to avoid in their own work.

While optimizing for a primary quality attribute like glycan profile, always measure secondary metrics such as aggregation and charge variance. The incremental cost is minimal since the cultures are already running, but the data can reveal critical, unforeseen effects that influence which candidates you advance.

The temptation is to use the most advanced technology available. A more effective approach is to first define the specific biological question and then select the simplest possible model that can answer it, thus avoiding premature and unnecessary over-engineering.

Instead of one massive experiment, split numerous factors into smaller, biologically-themed groups. Running these focused experiments in parallel is superior to both one-factor-at-a-time and large DOE approaches, as it maintains the breadth of a large screen while providing the high-quality signal of a small one.

A single, massive Design of Experiments (DOE) for screening many compounds is flawed. Adding numerous stock solutions causes dilution, untested combinations can be toxic to cells, and the strong effect of one compound can mask the subtler, yet crucial, effects of others, leading to poor data quality.